Search form



CL Mobile Menu

Nicotine-Receptor Partial Agonist Found Better Butt-Beater

Nicotine-Receptor Partial Agonist Found Better Butt-Beater

OXFORD, England, Jan. 24 -- Efforts to quit smoking with Chantix (varenicline), the nicotine receptor partial agonist, seems to be more successful than with Zyban (bupropion), according to a Cochrane review.

Successful long-term smoking cessation was about threefold more likely with Chantix than with unassisted quit attempts and about 1.5-times more likely compared with Zyban, said Kate Cahill, B.A., of the University of Oxford, and colleagues in a review published online in The Cochrane Library.

Although the six trials included in the review--all sponsored by Chantix maker Pfizer--established efficacy for the agent, the next step is to see how the drug measures up in independent trials, particularly against nicotine replacement therapy, the authors said.

"Direct comparisons with nicotine replacement therapy and further comparisons with bupropion would establish varenicline's relative effectiveness and safety," they wrote.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.